27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN) were trading higher by more than 9 percent early Friday morning after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 Annual Meeting.
Bio Blast Pharma is a clinical-stage biotechnology company that focuses on the treatment of orphan diseases. The company completed a Phase 2 six-month trial of its HOPEMD therapy in patients with oculopharyngeal muscular dystrophy (OPMD).
OPMD is a rare progressive muscle-wasting disease characterized by swallowing difficulties, leading to the risk of aspiration of food into the lungs, weight loss and muscle weakness.
The meeting will take place April 15 to 21 in Vancouver, Canada.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!